Theriva Biologics (TOVX) – Recent Trading Performance
- Current trading price (07:11 PM CET, Wednesday 21 Oct 2026): USD 0.21
- 24‑hour price change: +5 %
- Shares outstanding: 45.9 million
- Market capitalization: USD 9.4 million
- 24‑hour trading volume: USD 68.9 thousand
- Month‑end change (from last month’s close): –8.7 %
- 200‑day simple moving average: USD 0.24
- 52‑week high: USD 0.85 (24 Oct 2025)
- 52‑week low: USD 0.16 (23 Feb 2026)
Corporate Update – Special Stockholder Meeting
Theriva Biologics, Inc. has scheduled a special stockholder meeting for 18 November 2026 to vote on three proposals:
- Increase in authorized common shares to 500 million to expand capacity for future equity financing, strategic transactions, and incentive plans.
- Ratification of a prior warrant exercise allowing the issuance of up to 16 million shares upon exercise of warrants issued to institutional investors in a 2025 private placement.
- Adjournment provision allowing the meeting to be adjourned if the vote on the first two proposals is not decisive, providing the board and shareholders time to secure additional support.
The board recommends a vote in favor of all proposals. The meeting will be held at the company’s research and clinical development facility in Barcelona. Voting options include proxy, telephone, mail, or in‑person. Results will be reported in a Form 8‑K within a few days after the meeting.
24‑Hour Performance of Related Stocks
| Ticker | 24‑h Price Change | Current Price (USD) | Market Cap (USD) | Notable Recent Event |
|---|---|---|---|---|
| CJMB (Callan Jmb) | –65.62 % | 0.46 | 11 million | Received QuickStrip production line from Rapid Dose Therapeutics for Texas cGMP facility. |
| NOWVF (Nowvertical) | 0 % | 0.10 | 11.2 million | Closed first tranche of a private placement; CEO and Executive Chair appointments confirmed. |
| INAB (In8bio) | +4.59 % | 1.08 | 10.8 million | – |
| PTN (Palatin) | –7.85 % | 5.53 | 10.7 million | – |
| INTS (Intensity Therapeutics) | –0.3 % | 3.27 | 10.7 million | – |
Company Overview
- Name: Theriva Biologics, Inc.
- Industry: Biotechnology (Health Care)
- Headquarters: Rockville, United States
- Specialization: Adenovirus platform for IV, intravitreal, and antitumoral delivery; designed to induce tumor cell death, enhance delivery of co‑administered cancer therapies, and stimulate a sustained anti‑tumor immune response.
- Website: www.therivabio.com
- NYSE Ticker: TOVX
- IPO Date: 26 June 2006
This summary provides a concise, factual account of Theriva Biologics’ recent trading activity, upcoming corporate actions, and related market developments.
